Ligand Pharma (LGND) PT Raised to $262 at RBC Capital
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $254.50 -7.41%
Rating Summary:
14 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 10 | New: 23
Rating Summary:
14 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 10 | New: 23
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $262.00 (from $252.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Incyte (INCY) PT Raised to $105 at Truist Securities
- nCino Inc. (NCNO) PT Raised to $17 at JPMorgan
- Southern Co. (SO) PT Lowered to $99 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
